US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Abeona Therapeutics Inc. - Common Stock
(NQ:
ABEO
)
5.030
+0.020 (+0.40%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Abeona Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
September 29, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
September 22, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright
↗
September 22, 2026
Abeona Therapeutics (NASDAQ:ABEO) highlighted the early commercial progress of ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB),...
Via
MarketBeat
Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum
↗
September 22, 2026
Abeona Therapeutics (NASDAQ:ABEO) executives outlined the early commercial rollout of ZEVASKYN, an autologous cell sheet-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), during...
Via
MarketBeat
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
September 18, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
September 16, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
September 15, 2026
From
Pomerantz LLP
Via
GlobeNewswire
ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law
September 08, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
September 08, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
September 02, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
September 01, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona (ABEO) Q2 2026 Earnings Call Transcript
↗
August 20, 2026
ZEVASKYN revenue surged 31% to $11.4 million as treatment network expanded.
Via
The Motley Fool
Topics
Earnings
Abeona Therapeutics Q2 2026 Earnings Call Transcript
↗
August 13, 2026
Abeona Therapeutics (NASDAQ:ABEO) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For...
Via
Benzinga
Topics
Earnings
Abeona Therapeutics Q2 Earnings Call Highlights
↗
August 13, 2026
Abeona Therapeutics (NASDAQ:ABEO) reported second-quarter revenue growth from its ZEVASKYN cell therapy launch while outlining operational challenges involving patient scheduling and manufacturing that...
Via
MarketBeat
Topics
Earnings
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
August 13, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
August 06, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
August 04, 2026
NTAP Designation Expected to Support Medicare Patient Access, Treatment Center Economics and Commercial Adoption
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 03, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
July 21, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
May 26, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona (ABEO) Q1 2026 Earnings Transcript
↗
May 13, 2026
Abeona (ABEO) Q1 2026 Earnings Transcript
Via
The Motley Fool
Abeona Therapeutics Q1 Earnings Call Highlights
↗
May 13, 2026
Abeona Therapeutics (NASDAQ:ABEO) reported early commercial momentum for ZEVASKYN in the first quarter of 2026, with executives highlighting new patient treatments, expanded treatment-center activation...
Via
MarketBeat
Topics
Earnings
Abeona Reports Strong Q1 Revenue, Expands Treatment Center Network
↗
May 13, 2026
Abeona Therapeutics Inc. (NASDAQ: ABEO) reported first-quarter earnings Wednesday before the market opened. Here's a rundown of the report.
Via
Benzinga
Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
May 13, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®
May 11, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces Date of First Quarter Financial Results
May 04, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
